1 / 90

Hepatology Board Review

Hepatology Board Review. Hepatitis A. Enterically transmitted-RNA virus Common throughout the world but risk in developing nations Effective vaccine available No chronic state, <1% risk for FHF FHF usually if have underlying liver disease or older age

amena
Download Presentation

Hepatology Board Review

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatology Board Review

  2. Hepatitis A • Enterically transmitted-RNA virus • Common throughout the world but risk in developing nations • Effective vaccine available • No chronic state, <1% risk for FHF • FHF usually if have underlying liver disease or older age • No increase risk of FHF with pregnancy

  3. Hepatitis A IgM detectable at onset of symptoms and disappears by 3 months Hepatitis A IgG persists for years and indicates immunity Management Symptomatic therapy Hydration Rest Treat pruritus Enteric precautions Handwashing Prophylaxis – vaccine and Ig Hepatitis A

  4. Hepatitis E • Enterically-transmitted RNA virus • Endemic along equatorial regions • Central America, Mexico, Africa, Middle East, India, Asia, Southeast Pacific • HEVAB seen in 10-40% of adults > 25

  5. Hepatitis E • Fecal-oral spread (like HAV) • Person to person: Uncommon (unlike HAV) • Large outbreaks accounting for >50% of cases of acute sporadic hepatitis in adults and children in endemic areas • Severity associated with age and pregnancy • Mortality: 0.5-3.0%, pregnant pts:15-25%

  6. Hepatitis B • Outcomes after acute infection: • Infants - 90+% chronicity • Children - ~70% chronicity • Adults - <5% chronicty • Still #1 cause of HCC in world • Sexual and IVDU transmission common • Vaccine may eliminate in this country

  7. Hepatitis B • Must have HB s Ag positive • Then look at HB c Igs and e Ag/Ab • s Ab Positive denotes immune status (either by vaccine or infection) • Core- c Ab (IgG) defines infection w/ HBV but not protective • HBV DNA – detectable early, used to guide therapy

  8. Hepatitis B • To Assess: check serology (HBsAg, HBcAb, HBeAg, HBeAb), LFTs and liver biopsy as indicated • DNA level helpful with therapy • Assess presence of HCC (AFP, U/S vs. CT) • Assess status of liver disease- synthetic fxn (Alb,Bili,INR), presence stigmata CLD and portal HTN

  9. Serological Findings in HBV

  10. Asymptomatic Carriers + HBsAg Normal ALT - HBeAg HBVDNA < 103 Normal liver biopsy Low risk for cirrhosis/complications Active Disease +HBsAg +HBeAg HBV DNA > 104 +/- Abnormal ALT Active inflammation on liver biopsy Active replication/risk of transmission 15 to 40% risk of cirrhosis or complications Chronic HBV

  11. Chronic HBV Therapies available: • PEG interferon for 6-12 months • Nucleos(t)ides (lamivudine, adefovir, entecavir, telbivudine) • IFN may cause decomp in cirrhotics and withdrawal of nuc’s may cause flare HBV

  12. Hepatitis C • 1.8 % in US (about 4-5 million) • 85 % develop chronic infection • 8-20% develop cirrhosis • 5% will die of HCV • #1 reason for OLT today • Blood transfusion before 1992, IVDU, intranasal cocaine, tattoos, prison term, sexual transmission low

  13. Hepatitis C • HCV antibody by ELISA • RIBA- best used to confirm false pos Ab in low pretest probability group • HCV RNA (viral load) • Genotype • Liver biopsy

  14. Hepatitis C • Dual therapy with PEG Interferon and ribavirin is standard of care • Know: EVR, SVR, NR, relapser • Interferon alone yielded about 10-15% SVR • Ribavirin alone has NO role • Genotype 1 (noncirrhotic): 45-55% SVR (48-72 weeks tx) • Genotypes 2-3: 75-85% SVR (24 weeks tx)

  15. Hepatitis C TX CONTRAINDICATED if: • WBC < 3K • Platelets less than 70K (Lower now? 50K) • Severe depression • Renal failure • Untreated autoimmune disease • Decompensated liver disease with ascites/encephalopathy/variceal bleeds. (Tx is “liver transplant”!) • Retinopathy or neuropathy

  16. Hepatitis C Treatment side effects • Cytopenias; note hemolysis with ribavirin • Fatigue, viral symptoms • Depression and suicide • Auto-immune disorders (thyroid, Sjogren’s, SLE) • Teratogenesis with ribavirin (category X)

  17. Hepatitis C • Associated with cryoglobulinemia, PCT, MPGN, thyroid disease • Synergistic with alcohol and fat. • May be #1 cause of HCC in this country (caucasians) • HCC on the rise. Must screen cirrhotic patients with imaging and AFP q 6 months

  18. Reactivation Hep B • Something to consider in sick patients undergoing severe immunosuppression • Chemotx, BMT are the typical settings • PT with hx of HBcAb + (HBsAg negative) • Think about reactivation Hep B in immunosuppressed patients with jaundice, elevated LFTs • Extremely poor prognosis

  19. Alcoholic Liver Disease • Classic presentation of ETOH Hepatitis: RUQ pain/fever/jaundice (without biliary/gallbladder dz), leukocytosis • AST/ALT ratio >2, generally under 300-500 • Outcome assessment: Maddrey’s Discriminant Function = 4.6 x (PT - control PT) + bilirubin • DF > 32 high risk and merits steroids/Pentoxifylline • Caveat to steroids - not used with any signs of active infection or bleeding

  20. NAFLD/NASH • Common cause of LFTs < 4X nl, (if ETOH/Viral/other chronic hepatitis excluded). ALT>AST • Can be associated with progressive liver disease (#1 cause of cryptogenic cirrhosis) • Classic scenario: metabolic syndrome (overweight, impaired fasting glucose/DM, low HDL/high TG’s, SBP >130) • Liver biopsy can distinguish bland fatty liver from NASH • Treatment: weight loss, data on thiazolidinediones promising

  21. Autoimmune Hepatitis • Classic scenario-young female (there is a second peak in 60’s), constitutional sx’s, increased transaminases, globulin fraction, positive ANA and/or anti-smooth muscle antibodies • Treatment: steroids, azathioprine • Type 1 is “classic” w/ ANA/ASMA+ • Type 2 is anti-LKM1 Ab + (children)

  22. Primary Biliary Cirrhosis • Chronic cholestatic disease of middle aged mujeres • Sx: pruritus, fatigue • Most are asymptomatic at diagnosis (classically e alk phos and + anti-mitochondrial antibody [AMA]) • Other immune disease assoc: Sjogrens, CREST, scleroderma, celiac disease • UDCA works to delay/prevent cirrhosis and transplant

  23. Primary Sclerosing Cholangitis • Middle aged males with ulcerative colitis • 70% of pts with PSC have UC; 7% of pts with UC have PSC • Diagnose by finding beaded intra- and extrahepatic bile ducts on imaging (MRCP or ERCP) • Colitis and PSC - very high risk of colonic cancer • Treatment: none work, best is liver transplant (when severe) • 10% develop cholangiocarcinoma

  24. Fulminant Hepatic Failure • FHF = encephalopathy within 8 weeks of onset of sx • Elevated liver tests, TBili, or INR do not equal FHF in absence of encephalopathy • Major complications - cerebral edema (#1 cause death), infection, coagulopathy, renal failure • Treatment: support in ICU, then transplant

  25. Fulminant Hepatic Failure

  26. Liver Transplantation • Indicated in chronic liver pt with < 80-90% survival at 1 yr. Listing criteria now based on MELD (Bili, INR, Creat) - refer when MELD > 15 • “Status 1” = Fulminant hepatic failure • Contraindications: AIDS (HIV relative contraindication), extrahepatic malignancy, advanced cardiopulmonary disease, active drug/ETOH, MOSF, active infection, large liver tumor (>5 cm) or >3 tumors (>3cm), age>70

  27. Drug-Induced Liver Disease • Idiosyncratic (most) vs. dose related (e.g. Tylenol) • Hepatitis-like: INH, NSAIDs, sulfa • Cholestatic: estrogens, anabolic steroids, Augmentin, • Peliosis hepatis: anabolic/androgenic steroids, contraceptives • Fulminant: INH, acetaminophen, antbx’s • Steatosis: valproate, MTX, amiodarone, HAART • Granulomas: allopurinol, hydralazine, quinidine, procainamide

  28. Acetaminophen • #1 cause of FHF in US/UK • Usually more than 10g single dose (can be less in ETOH abuse), • Treatment: NG lavage/charcoal if < 4 hours, NAC 140 mg/kg load then 70 mg/kg q4h for 17 doses • Criteria for predicting HIGH mortality and need to be in transplant center: pH<7.3 OR, INR>6.5 + creatinine>3.4 + coma, OR factor V less than 10 % (i.e. King’s College criteria) • “Therapeutic misadventures”

  29. Hemochromatosis • Prevalence 1/250-300 Northern European descent, carrier rate 1/10-12 people • Autosomal recessive dz; HFE gene on Chromosome 6 • Accumulate iron through life • Cirrhosis starting in 40s • Iron also in heart, joints (fingers/wrist), pancreas, skin, pituitary, testes

  30. Hemochromatosis

  31. Hemochromatosis • Iron sat > 45% • Ferritin >1000 • HFE gene mutation is BEST TEST (homozygous for C282Y mutation or compound hetero for C282Y/H63D) • Liver biopsy – not needed for dx, useful to determine extent of liver disease

  32. Hemochromatosis

  33. Hemochromatosis • Phlebotomy for life (keep ferritin < 50) • Screen for cirrhosis and HCC • Refer for OLT if indicated. • If iron removed before cirrhosis; normal life expectancy • Complications: cirrhosis, HCC, cardiomyopathy, DM, hypogonadism • Need to recommend family screening: 25% chance in siblings, 5% in kids

  34. Wilson’s Disease • Rare disease (1 in 30,000 incidence) • Defect on chromosome 13 • Inability to transport copper within the hepatocyte • Deficiency of biliary copper excretion • Poor incorporation of copper into ceruloplasmin • Excess total body copper • Liver, brain, kidney, bone, cornea/lens, RBC

  35. Wilson’s Disease • Clinical presentation (usually before age 40) • Hepatic – acute/chronic hepatitis, ALF, cirrhosis • Neurologic – motor disorders • Psych – depression, personality changes, phobias • Lab diagnosis • Low serum ceruloplasmin • 24 hour urine copper • Liver copper • Tx: penicillamine, trientine, zinc • OLT for ALF or decompensated cirrhosis • Family screening!

  36. Alpha-1 Antitrypsin Deficiency • Most common metabolic disease of the liver • AAT degrades proteases (neutrophil elastase) • Increased risk of lung and/or liver disease • can have without the other • PiMM - normal phenotype • PiZZ phenotype - leads to disease • Dx: AAT phenotyping, liver bx to confirm • Tx: no tobacco, liver transplant for severe liver disease (lung disease consider AAT replacement therapy)

  37. Alpha-1 Antitrypsin Deficiency

  38. Budd-Chiari Syndrome • Hallmark is hepatic venous outflow obstruction • can occur from hepatic venules to right atrium • “classic” form = hepatic vein obstruction • Etiology: • Western countries: thrombosis from myeloproliferative (PCV), hypercoag states, OCP use • Asia/Africa: IVC webs • Hepatomegaly, RUQ pain, ascites

  39. Budd-Chiari Syndrome • Dx: Doppler US to visualize clot/lack of flow in hepatic veins • Tx: • anticoagulation, diuretics • decompression -TIPS or surgical portosystemic shunt. OLT for decompensated cirrhosis or failed shunts • NB: Sinusoidal obstruction syndrome - complication of bone marrow transplant. Hint is immediate weight gain (ascites) and jaundice 10-20 days after transplant

  40. Ischemic Hepatopathy • MARKED increase in ALT/AST - up to 100 x ULN - followed by rapid decline over 7 to 10 days. • Clue: marked bump in LDH and rise in creatinine • Can occur post resuscitation or low BP event • short latency (24 hours) after event • No liver specific therapy usually needed • Rarely leads to FHF and never causes cirrhosis

  41. Cirrhosis • Assess etiology: Rx specific • #1 cause in US – alcohol • NASH rising fast • Assess severity: Child’s class, MELD score • Assess OLT candidacy • Eval for decompensation: ascites, varices, PSE; prophylaxis as indicated • Screen for HCC : US and AFP every 6 months • Immunize against HAV/HBV

  42. Operative Risk • Acute Hepatitis - high mortality 9.5% • Bottom line: avoid surgery unless life-saving • Cirrhosis - Child’s Classification (TBili, Alb, ascites, PSE, and PT/INR) • A: 10% • B: 31% • C: 76% • MELD is being increasingly used for pre-op risk stratification

  43. Postoperative Jaundice • Intrahepatic Cholestasis: • Parenchymal disease: anesthesia, drugs, TPN, sepsis, ischemia • Increased bili load: transfusions, hemolysis, hematoma reabsorption, Gilbert’s • Extrahepatic Cholestasis: CBD stones, stricture, pancreatitis, acalculous cholecystitis • Undiagnosed cirrhosis pre-op up to 50% will develop jaundice post-op

  44. Varices Esophageal Gastric

  45. Variceal Hemorrhage • Most serious complication of portal HTN • 1/3 of cirrhosis-related deaths • 40-60% of cirrhosis pts develop varices • 30% of these pts will bleed within 2 yrs of dx • 30% mortality with bleeding episode • Rebleed risk is 30-55% • Best predictor of bleeding is variceal size • All patients with large varices should receive primary prophylaxis • Non-selective beta-blockers – current standard of care • Banding – reserved for BB failure/contraindications

  46. Variceal Hemorrhage • Treatment Modalities • Medical: • Octreotide, somatostatin, terlipressin, vasopressin • Antibiotic prophylaxis • Endoscopic: band ligation (sclerotherapy is second line treatment) • Balloon tamponade – temporary fix only • TIPS – reserved for failure of above • Tissue adhesive (fibrin glue) – for gastric varices • Avoid overresuscitation (increases splanchnic pressures) • Initial treatment successful in 90% • Continued banding and beta-blockers for secondary prophylaxis as outpatient

  47. Ascites • Most common form of decompensation in cirrhosis • 85% of cases of ascites are due to cirrhosis • Physical exam • Checking for flank dullness followed by shifting dullness is best test • Checking for a fluid wave or puddle sign (cruel) is poorly sensitive/specific

  48. Paracentesis - Indications • New onset ascites • ANY hospital admission for ANY patient with ascites (unexpected SBP in 10 - 27%) • Patients with ascites who demonstrate clinical deterioration • Evaluation of response to treatment for SBP • Therapeutic paracentesis for tense ascites

More Related